In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
SHEZF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.94 Med: 6.14 Max: 32.77
Current: 2.94
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Shenzhen Hepalink Pharmaceutical Group Co was 32.77. The lowest was 2.94. And the median was 6.14.
SHEZF's Price-to-Net-Current-Asset-Value is ranked better than 71.8% of 610
companies
in the Drug Manufacturers industry
Industry Median: 5.675
vs SHEZF: 2.94
Shenzhen Hepalink Pharmaceutical Group Co (OTCPK:SHEZF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Shenzhen Hepalink Pharmaceutical Group Co Net Current Asset Value Related Terms
Shenzhen Hepalink Pharmaceutical Group Co Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co Net Current Asset Value Chart
Shenzhen Hepalink Pharmaceutical Group Co Annual Data
SHEZF vs ZTS, UTHR: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Hepalink Pharmaceutical Group Co Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shenzhen Hepalink Pharmaceutical Group Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Shenzhen Hepalink Pharmaceutical Group Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.47 mean?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a Net Current Asset Value of $0.47 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. This is 92% below median its historical median of 6.14. Over the past decade, Shenzhen Hepalink Pharmaceutical Group Co's Net Current Asset Value has ranged from 2.94 to 32.77. According to the industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #172 out of 610 companies in the Drug Manufacturers industry, placing it in the top 28.2%.
Is Shenzhen Hepalink Pharmaceutical Group Co's Net Current Asset Value too high?
Shenzhen Hepalink Pharmaceutical Group Co's current Net Current Asset Value of $0.47 is 92% below median its 10-year median of 6.14. Over the past 10 years, this metric has ranged from a low of 2.94 to a high of 32.77. The Drug Manufacturers industry median Net Current Asset Value is 5.68. Shenzhen Hepalink Pharmaceutical Group Co's value of $0.47 is 91.7% below this industry median. Based on the distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #172 out of 610 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #172 out of 610 companies for Net Current Asset Value. This puts Shenzhen Hepalink Pharmaceutical Group Co in the upper half of its industry. The industry median Net Current Asset Value is 5.68. Shenzhen Hepalink Pharmaceutical Group Co's value of $0.47 is 91.7% below this benchmark. Historically, Shenzhen Hepalink Pharmaceutical Group Co's own Net Current Asset Value has ranged from 2.94 to 32.77 over the past decade. While the company's 10-year median is 6.14 vs. the industry median of 5.68, Shenzhen Hepalink Pharmaceutical Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.68, based on 610 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Hepalink Pharmaceutical Group Co's current Net Current Asset Value of $0.47 is 91.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Hepalink Pharmaceutical Group Co's current Net Current Asset Value is $0.47, which is 92% below median its own 10-year median of 6.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current Net Current Asset Value of $0.47. The stock's GF Value™ is $0.56, compared to a current price of $0.47 — trading 16.1% below its estimated fair value. The current Net Current Asset Value is $0.47, which is 92% below median its 10-year median of 6.14 and 91.7% below the Drug Manufacturers industry median of 5.68. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current Net Current Asset Value is $0.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of $0.47 is trading 16.1% below its estimated GF Value™ of $0.56.
Key valuation signals for SHEZF:
Net Current Asset Value: $0.47 (92% below median its 10-year median of 6.14)
GF Value™: $0.56 vs. price of $0.47 (16.1% below fair value)
Industry Position: 91.7% below the Drug Manufacturers median (#172 of 610)
No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Hepalink Pharmaceutical Group Co Business Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
69GF Score
Get the complete analysis for SHEZF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHEZF has been successfully added to your 
